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ARTICLE
A human endothelial cell-based recycling assay for
screening of FcRn targeted molecules
Algirdas Grevys1,2, Jeannette Nilsen2,3, Kine M.K. Sand1,2, Muluneh B. Daba1,2, Inger Øynebråten4, Malin Bern1,2,
Martin B. McAdam1,2, Stian Foss1,2, Tilman Schlothauer5, Terje E. Michaelsen6,7, Gregory J. Christianson8,
Derry C. Roopenian8, Richard S. Blumberg9, Inger Sandlie1,2 & Jan Terje Andersen1,2,10
Albumin and IgG have remarkably long serum half-lives due to pH-dependent FcRn-mediated
cellular recycling that rescues both ligands from intracellular degradation. Furthermore,
increase in half-lives of IgG and albumin-based therapeutics has the potential to improve their
efficacies, but there is a great need for robust methods for screening of relative FcRn-
dependent recycling ability. Here, we report on a novel human endothelial cell-based recy-
cling assay (HERA) that can be used for such pre-clinical screening. In HERA, rescue from
degradation depends on FcRn, and engineered ligands are recycled in a manner that corre-
lates with their half-lives in human FcRn transgenic mice. Thus, HERA is a novel cellular assay
that can be used to predict how FcRn-binding proteins are rescued from intracellular
degradation.
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S ince the development of the hybridoma technology around40 years ago1, monoclonal antibodies have become impor-tant therapeutics, particularly for the treatment of cancer
and autoimmune diseases2,3. Antibody engineering initially
focused on humanization as well as improvement of antigen
affinity4. There has been more recent interest in fine-tuning of the
Fc region2,4. The major antibody class found in the blood, IgG,
has a remarkable persistence, with a serum half-life of 20–23 days,
compared with only hours or a few days for other circulating
proteins5. The only exception is albumin, which has a similar long
half-life, and is utilized as carrier for therapeutics6,7. In both
cases, the long half-life is due to their molecular size above the
renal clearance threshold and their interaction with a membrane-
bound receptor named the neonatal Fc receptor (FcRn).
FcRn is an MHC class I-related molecule that consists of a
transmembrane heavy chain (HC) that non-covalently associates
with β2-microglobulin8–10. The receptor binds both ligands non-
competitively in a strictly acidic pH-dependent manner, with
negligible binding and release at neutral pH11–14. While FcRn
binds the CH2–CH3 elbow region of IgG, both domain I and III
of albumin are required for optimal binding to the
receptor13,15,16.
Advanced imaging studies have demonstrated that FcRn is
predominantly located within acidified endosomes, where the low
pH allows binding of IgG taken up by fluid-phase pinocytosis17.
FcRn then recycles its IgG to the cell surface for release into the
circulation upon exposure to the physiological pH of the blood18–
20. Proteins that do not bind the receptor are directed to lyso-
somal degradation. As albumin binds FcRn in a similar pH-
dependent manner12,14,21,22, recent data support that it follows
the same recycling pathway23. Further, FcRn expressed by
endothelial cells regulate both ligands, hematopoietic cells
determine IgG homoeostasis while hepatocytes regulate albumin
but not IgG24–27.
Several studies have demonstrated the shortcomings of stan-
dard laboratory mice as pre-clinical models for evaluation of
human IgG (hIgG) and human serum albumin (HSA) pharma-
cokinetics, due to considerable differences in binding kinetics
towards mouse and human FcRn (hFcRn)28–31. Specifically,
hFcRn binds weakly to mouse IgG (mIgG), whereas mouse FcRn
(mFcRn) binds more strongly to hIgG than to mIgG28,29,31. The
lack of binding of mIgG to hFcRn explains why murine anti-
bodies are rapidly removed from the circulation in humans,
despite long half-life in mice32. Injected recombinant IgG variants
compete with endogenous ligands for FcRn binding, and the
strong interaction between mFcRn and hIgG explains why the
half-life of hIgG is longer than that of mIgG in WT mice28,33,34.
Furthermore, both the mouse and human receptors bind more
strongly to mouse serum albumin (MSA) than to HSA. Impor-
tantly, mFcRn binds HSA very poorly29, and consequently, HSA
has a short half-life in WT mice35,36. Mice that are knock-out for
mFcRn and transgenic for hFcRn have lower levels of mIgG and
higher levels of MSA than what is found in WT mice21,37. Due to
the high MSA levels, HSA also have short half-life in these mice35.
Recently, hFcRn transgenic mice that lack MSA expression have
been developed, and injected HSA shows considerably extended
half-life of more than 20 days in these mice36.
Development of engineered IgG and albumin molecules with
improved pharmacokinetics requires efficient screening proce-
dures in which FcRn binding and cellular transport can be
quantitatively closely monitored6,7. A major challenge in Fc-
engineering for improved pharmacokinetics is to increase the
binding affinity for FcRn at acidic pH without a concomitant
increase in affinity at near neutral pH. This is crucial, as low
affinity at near neutral pH is a prerequisite for efficient recycling
and exocytosis, and one is faced with the same challenge when
engineering the FcRn–albumin interaction. Furthermore, such
engineering affects binding to the mouse and human receptors
differently28,30, making it even more difficult to make reliable
predictions. Except for advanced imaging analysis of molecular
sorting and trafficking, no easy and robust in vitro cellular assay is
available that allows predictions to be made on how well engi-
neered IgG and albumin variants are rescued from intracellular
degradation. Here, we report on a human endothelial cell-based
recycling assay, abbreviated HERA, which is established to enable
such screening of IgG and albumin variants, prior to evaluation in
transgenic mice or non-human primates. Only small amounts of
ligands are required, and there is no need for chemical labelling.
Results
HERA. We utilized a previously described human microvascular
endothelial cell (HMEC1) line that grows as adherent mono-
layers. It is modified to stably express human β2-microglobulin
and the full-length hFcRn HC with an N-terminal HA-tag and
EGFP-fused C-terminally (HMEC1-hFcRn)38. The expression of
hFcRn was measured to be >100-fold higher than in the parental
cell line (Supplementary Fig. 1a–c). We grew the HMEC1-hFcRn
cells in wells until 95–100% confluency, removed the medium
and incubated the cells for 1 h in HBSS buffer at pH 7.4. Sub-
sequently, fresh buffer at pH 7.4 or pH 6.0 containing the proteins
of interest were added, followed by incubation to allow for
uptake. We found that an incubation step of 4 h was sufficient
(Supplementary Fig. 2a). After washing, the cells were again
incubated for 4 h with buffer at pH 7.4 to allow for ligand release
(Supplementary Fig. 2b). The amount of ligand that was taken up
after the first 4 h incubation and the ligand recycled after addi-
tional 4 h was quantified by enzyme-linked immunosorbent assay
(ELISA). In addition, we quantified the amounts remaining inside
the cells after the recycling step by running ELISA on cell lysates.
An illustration of the HERA principle is given in Fig. 1.
To address the effect of extracellular pH on rescue, titrated
amounts of IgG were given at either pH 7.4 or pH 6.0 followed by
washing and additional 4 h incubation at pH 7.4. The antibody
used was a chimeric hIgG1 with mouse lambda light chain, hIgG1
constant HC, and a VH providing specificity for the hapten 4-
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Fig. 1 The HERA protocol. a HMEC1-hFcRn cells are seeded and grown until confluent. b Cells are washed and starved for 1 h using HBSS (pH 7.4). c The
protein of interest is diluted in HBSS (pH 7.4 or 6.0) and added to cells and incubated for 4 h. dMedium is removed and cells are extensively washed with
ice cold HBSS (pH 7.4) before the cells are lysed or e pre-heated HBSS (for 4 h incubation) or growth medium (for overnight incubation (ON)) is added,
incubated and samples collected. f Cells are extensively washed with ice cold HBSS (pH 7.4) and lysed. g The collected samples are analysed in ELISAs
specific for IgG or albumin
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hydroxy-3-iodo-nitrophenylacetic acid (NIP). The amounts of
anti-NIP antibody released from the cells were quantified, and at
both pH conditions, concentration-dependent recycling was
measured. However, roughly 10-fold more WT hIgG1 was
released when the initial incubation step was performed at pH
6.0 (Fig. 2a, b). Thus, acidification during the incubation step
sensitizes the assay.
Next, we compared recycling of the WT antibody with that of a
hIgG1 variant containing three amino acid residue substitutions
in the CH2 and CH3 domains of the Fc (I253A/H310A/H435A;
hIgG1-IHH) (Fig. 2c), which eliminate IgG binding to hFcRn26.
In addition, we included a recombinant anti-NIP WT mIgG1.
When equal amounts of the antibodies were added to the cells at
pH 7.4, both hIgG1-IHH and mIgG1 were found to be recycled
poorly (Fig. 2d, e). This was as expected, as mIgGs bind only
weakly to hFcRn28,29,31. Further, we found that HMEC1-hFcRn
cells treated with a mixture of siRNAs targeting the hFcRn HC
gene downregulated the protein level by nearly 80% for up to 96 h
(Supplementary Fig. 3a–b), which resulted in reduced recycling of
WT hIgG1 by 90% compared with cells given control siRNA
(Fig. 2f). Lastly, cells were incubated with WT hIgG1 in the
presence of three monoclonal mouse antibodies raised against
hFcRn, which block the binding site for IgG (DVN24), the
binding site for albumin (ADM31), or the binding of neither
ligand (ADM12)39,40. In the presence of DVN24, IgG recycling
was abolished, while ADM31 did not interfere and ADM12 gave a
minor reduction (Fig. 2g–i). Thus, recycling of hIgG1 was fully
dependent on hFcRn.
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Fig. 2 Recycling of IgG is dependent on FcRn. Recycling of WT hIgG1 at a pH 7.4 and b pH 6.0 after 4 h incubation with titrated antibody concentrations
(100–1600 nM). c An illustration of the hIgG1 Fc crystal structure where the mutated residues in hIgG1-IHH (I253A, H310A and H435A) are highlighted in
red. The figure was designed by using the PyMOL software with the crystallographic data of hIgG1 Fc69. The amount (ng) recycled for each of the hIgG1
variants was used to calculate relative recycling compared with the WT that was set to 1.0. Histograms showing relative recycling of dWT and hIgG1-IHH,
e WT hIgG1 and mIgG1, and f WT hIgG1 by HMEC1-FcRn cells transfected with control or hFcRn-specific siRNAs. Relative recycling of WT hIgG1 in the
presence of g DVN24 (binds the IgG binding site on hFcRn), h ADM31 (binds the HSA binding site on hFcRn) and i ADM12 (does not bind the ligand
binding sites) are shown. Obtained data are given as mean± s.d. of three independent experiments performed in duplicates
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Imaging of uptake and rescue of IgG. To visualize hIgG1 uptake
and release as a function of pH, we performed live cell confocal
imaging of HMEC1-hFcRn cells. The cells were grown to 50–70%
confluency before Alexa-647-conjugated WT hIgG1 or hIgG1-IHH
was added at pH 6.0 and incubated for 4 h. Imaging revealed a high
degree of co-localization of WT hIgG1 with the EGFP-fused
receptor, suggesting that WT hIgG1 localized to recycling endo-
somes (Fig. 3a, b). After further incubation at pH 7.4, only low
signals for the antibody were observed, suggesting that most of the
antibodies had been released to the medium and a minor fraction
sorted to the lysosomes (Fig. 3c, d). In contrast, we detected only
minor co-localization of hFcRn-EGFP with Alexa-647-conjugated
hIgG1-IHH at pH 6.0 whereas a larger fraction of the antibody was
co-localized with a lysosomal marker (Fig. 3e, f). After buffer
exchange to pH 7.4, even more hIgG1-IHH co-localized with the
lysosomal marker (Fig. 3g, h). In addition, the set-up was repeated
where both incubation steps were performed at neutral pH and the
imaging results revealed that uptake of WT hIgG1 and hIgG1-IHH
were similar at pH 7.4 (Supplementary Fig. 4a–d). The major
fraction of WT hIgG1 was shown to co-localize with FcRn-positive
endosomes (Supplementary Fig. 4b) while most of hIgG1-IHH was
localized to lysosomes (Supplementary Fig. 4d).
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Fig. 3 Visualization of FcRn-mediated transport of IgG in HMEC1-hFcRn cells. HMEC1-hFcRn cells were seeded in eight-well NuncTM Lab-TekTM
chambered Coverglass imaging dishes, and live cell imaging was performed the day after. a Cells were washed three times with HBSS pH 6.0 and incubated
with 400 nM Alexa-labelled WT hIgG1 diluted in HBSS pH 6.0 for 4 h at 37 °C. Cells were incubated with Lysotracker DND-99 for 30min before washed
with HBSS pH 6.0 and images were taken. b WT hIgG1 co-localization with FcRn-positive endosomes or lysosomes after 4 h incubation (n= 20 cells). c
The same cells as in a were washed three times with HBSS pH 7.4 followed by additional 4 h incubation at 37 °C before images were taken. dWT hIgG1 co-
localization with FcRn-positive endosomes or lysosomes after additional 4 h incubation (n= 19 cells). e Cells were washed three times with HBSS pH 6.0
and incubated with 400 nM Alexa-labelled hIgG1-IHH diluted in HBSS pH 6.0 for 4 h at 37 °C. Cells were incubated with Lysotracker DND-99 for 30min
and washed with HBSS pH 6.0 before images were taken. f hIgG1-IHH co-localization with FcRn-positive endosomes or lysosomes after 4 h incubation (n=
16 cells). g The same cells as in e were washed three times with HBSS pH 7.4 followed by additional 4 h incubation at 37 °C before images were taken. h
hIgG1-IHH co-localization with FcRn-positive endosomes or lysosomes after additional 4 h incubation (n= 15 cells). Representative confocal images at each
condition are shown. Large scale bar—10 µm; small scale bar—2 µm. Co-localization analyses were performed using Imaris spot co-localization. Data are
shown as mean± s.d. from two independent experiments were n= 20 (b), 19 (d), 16 (f) and 15 (g) cells
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03061-x
4 NATURE COMMUNICATIONS |  (2018) 9:621 |DOI: 10.1038/s41467-018-03061-x |www.nature.com/naturecommunications
FcRn binding properties of Fc-engineered hIgG1 variants.
Next, we compared WT hIgG1 with four previously described
hIgG1 variants Fc engineered for altered FcRn-binding kinet-
ics28,41–43, all with NIP specificity44. Two of the antibodies have
two substitutions in the CH3-domain, M428L/N434S (hIgG1-LS)
and H433K/N434F (hIgG1-KF), the third variant has three sub-
stitutions in CH2, M252Y/S254T/T256E and two in the CH3-
domain, H433K/N434F (hIgG1-YTE/KF), while the fourth has
the three CH2 mutations only (hIgG1-YTE) (Fig. 4a). The
binding affinities of purified antibody preparations were deter-
mined using MicroScale Thermophoresis at both pH 5.5 and pH
7.4, by adding different concentrations of monomeric hFcRn to a
constant amount of labelled hIgG1 variants (Fig. 4b–f). The
results obtained at pH 5.5 revealed a hierarchy of FcRn binding
relative to WT (KD = 0.9 μM) as follows: YTE/KF bound 100-fold
more strongly, LS and KF showed similar binding affinities and
bound 22- and 18-fold stronger, respectively, while YTE was the
weakest binder with a 6-fold increase in affinity. At pH 7.4, the
WT bound very weakly (>60 μM) followed by 3-fold stronger
binding of YTE, while the LS and KF variants bound approxi-
mately 9-fold and 18-fold more strongly than the WT, whereas
YTE/KF again was the strongest binder with more than 75-fold
enhanced binding (Table 1).
FcRn-mediated recycling is a dynamic process that occurs
through a pH gradient. To investigate how Fc-engineering
affected dissociation from hFcRn as a function of pH, we added
the antibodies onto an hFcRn-coupled affinity column at pH 6.0
and detected elution as the pH of the buffer was gradually
increased towards pH 8.8 (Fig. 4g, Supplementary Table 1). The
hIgG1 variants showed distinct profiles, where dissociation of the
WT peaked at pH 7.0. YTE, LS and KF eluted with peaks in the
pH range of 7.7–8.0. As expected, YTE/KF was released from the
column at the highest pH, at 8.5. Thus, the Fc-engineered variants
showed distinct pH-dependent binding kinetics as well as pH
elution profiles.
HERA screening of Fc-engineered hIgG1 variants. HERA was
performed on the Fc-engineered hIgG1 variants as described
above. We quantified the amounts of hIgG1 variants present
inside the cells after 4 h incubation at pH 7.4 and compared with
WT. The results showed 5-fold more YTE and LS, 8-fold more KF
and 13-fold more YTE/KF (Fig. 5a, d). Quantification of the
amounts of antibody released from the cells after washing and the
second 4 h incubation with fresh medium showed 6-fold more
YTE and LS, 9-fold more KF and 13-fold more of the YTE/KF
variant than WT (Fig. 5b, e). Quantification of the amounts that
remained in the cells at termination of the assay revealed that 3-
fold more YTE and LS, 10-fold more KF and 50-fold more YTE/
KF accumulated compared to WT (Fig. 5c, f). The release step
could also be run overnight without affecting the relative
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Fig. 4 hFcRn binding characteristics of Fc-engineered IgG variants. a Illustrations of the crystal structure of hIgG1 Fc (blue) with the amino acid residues
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variants. The antibody elution profiles are shown as relative fluorescence intensity and as a function of a pH gradient
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differences between the hIgG1 variants and WT (Supplementary
Fig. 5a–c).
We then investigated how initial exposure of the antibodies to
the cells at pH 6.0 followed by washing and incubation at pH 7.4
affected uptake, release and amount remaining inside the cells
(Fig. 5g–i). After the 4 h incubation at pH 6.0, we detected 3-fold
more YTE and LS than that of WT inside the cells, as well as 3.5-
and 4-fold more KF and YTE/KF, respectively (Fig. 5g). More-
over, 4–5-fold more of all the variants, including YTE/KF, were
detected in the medium compared to the WT (Fig. 5h). However,
the amounts of the antibodies remaining inside the cells after
additional 4 h incubation at pH 7.4 were roughly the same as
when all steps were performed at pH 7.4 (Fig. 5c, i). We also
treated the cells with a mixture of siRNAs targeting the hFcRn
HC to address whether the receptor was required for uptake, and
found that it was not crucial for WT hIgG1, but that YTE/KF was
less efficiently taken up when the receptor was downregulated
(Supplementary Fig. 6a, b). Next, we calculated a so-called HERA
score for each of the hIgG1 variants by dividing the relative
difference in recycling (Fig. 5e) by the relative difference in
residual amount (Fig. 5f). The estimations gave the highest score
for YTE and LS while KF gave a similar score as the WT, and
YTE/KF showed the lowest (Fig. 6a).
HERA score correlates with half-life values in hFcRn mice. To
assess whether the HERA score could be used to predict the half-
life of WT and the Fc-engineered hIgG1 variants, we measured
the serum half-life in hFcRn transgenic mice after injection of
equal amounts of antibody. The derived serum pharmacokinetic
profiles showed that YTE and LS exhibited increased serum
persistence compared with WT, resulting in half-life values of
12.6 and 11.2 vs 8.4 days, respectively (Fig. 6b, Table 2). Further,
the KF variant was cleared somewhat faster than the WT with a
half-life of 7.6 days while YTE/KF showed the shortest half-life
(Fig. 6b, Table 2). Notably, none of the hIgG1 Fc-engineered
variants showed increased serum persistence in WT mice
(Fig. 6c). The HERA scores were then plotted toward the serum
half-lives obtained in WT and hFcRn transgenic mice (Fig. 6d, e).
We found a significant correlation with half-life in humanized
mice (p-values of 0.0014), but not in WT mice (p-values of
0.2169). The remarkable differences in half-life of the hIgG1 Fc-
engineered variants between the mouse strains are reflected by
their distinct binding properties for the mouse and human forms
of the receptor, where mFcRn binds more strongly to the anti-
bodies but less pH dependently (Supplementary Fig. 7a–d).
FcRn-mediated recycling of albumin in HERA. As FcRn does
not only bind IgG, but also albumin, we adopted HERA to study
recycling of WT HSA at different concentrations at either pH 7.4
or 6.0. Release into the medium was quantified using ELISA, and
at both pH conditions, concentration-dependent release was
measured. Roughly three-fold more of HSA was detected in the
medium when initial uptake was performed at pH 6.0 (Fig. 7a, b).
Next, we tested how a mutant variant containing a single-point
mutation in domain III (K500A) (Fig. 7c), which reduces binding
to hFcRn by 30-fold14, and also MSA, which binds more strongly
than HSA to hFcRn29,35, were recycled. MSA was recycled more
efficiently than HSA, whereas the K500A mutant was poorly
recycled compared with the WT (Fig. 7d, e). In addition, down-
regulation of the hFcRn HC expression levels with siRNA resulted
in a reduction of almost 70% (Fig. 7f), while addition of ADM31
reduced recycling of HSA by nearly 90% (Fig. 7g). Only a modest
reduction was shown in the presence of DVN24 or ADM12
(Fig.7h, i).
Furthermore, we previously reported on an HSA variant with a
single amino acid substitution in the C-terminal end of domain
III (K573P) (Fig. 7c), which extended the serum half-life from 5.4
to 8.8 days in cynomolgus monkeys35. MicroScale Thermophor-
esis analysis revealed that K573P bound hFcRn 10-fold more
strongly than WT at pH 5.5 and only very weakly at pH 7.4 (>70
µM), while WT had no detectable binding at pH 7.4 (Table 1,
Fig. 7j, k). Analysis of the elution profiles on the hFcRn-coupled
column showed that the WT and the K573P variant dissociated
from the receptor at pH 6.4 and 6.9, respectively (Fig. 7l,
Supplementary Table 1). Thus, HSA dissociate earlier than that of
WT hIgG1 (Fig. 4g, Supplementary Table 1). Using HERA, four-
fold more K573P than WT was detected inside the cells after
uptake, and also six-fold more was released during the recycling
step (Fig. 7m, n) as well as two-fold more remained inside the
cells (Fig. 7o). The findings demonstrate that hFcRn expressed by
endothelial cells rescues not only hIgG1, but also HSA from
degradation and that engineering for enhanced FcRn binding
translates into more efficient recycling and release.
FcRn transport of its two ligands. In vitro studies have shown
that recombinant soluble FcRn binds IgG and albumin to sepa-
rate binding sites in a non-cooperative manner12,16,21,22. How-
ever, whether the presence of one ligand interferes with binding
and sorting of the other in a cellular context has not yet been
addressed. Thus, we studied uptake and release of WT hIgG1 and
HSA when excess amounts of the other ligand were added. Equal
amounts of WT hIgG1 (anti-adenovirus 5 hexon capsid protein)
or WT HSA were added in the presence of rituximab (8 µM) or
anti-NIP hIgG1-YTE/KF (2 µM) (Fig. 8a–d). The results revealed
that the presence of YTE/KF reduced recycling of WT hIgG1 by
50%, while no reduction was detected when rituximab was added
Table 1 KD values derived from MicroScale Thermophoresis analysis
KD ± s.d. (nM) pH
5.5
KD ± s.d. (µM) pH
7.4
Fold difference compared
with WT pH 5.5
Fold difference compared
with WT pH 7.4
hIgG1 variants
WT 964.3± 128.0 >60
YTE 166.4± 20.1 >20 5.8 >3
LS 43.6± 8.3 7.0± 2.0 22.0 >9
KF 53.4± 10.4 3.3± 0.9 18.0 >18
YTE/KF 9.3± 5.3 0.8± 0.2 107.0 >75
HSA variants
WT 520.5± 96.5 NA*
K573P 49.6± 8.5 >70 10.0 NA
* NA not acquired
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(Fig. 8b). Decreased levels were also detected for WT hIgG1
inside the cells, due to faster degradation expected in the absence
of hFcRn available for binding (Fig. 8a), while uptake and rescue
of HSA was unaffected except for a slight increase in rescue in the
presence of an excess amount of rituximab (Fig. 8c, d).
Furthermore, we measured uptake and recycling of WT anti-
NIP hIgG1 in the presence of WT HSA (8 µM) or an engineered
HSA variant (E505Q/T527M/V547A/K573P; EQTMVAKP) (2
µM) that binds hFcRn strongly and less pH dependently
(Supplementary Fig. 8). While the engineered HSA variant did
not affect uptake, the presence of WT HSA reduced uptake of
hIgG1 by roughly 50% (Fig. 8e). Despite this, the amount of
hIgG1 taken up was as efficiently recycled, as in the absence of
WT HSA, while blocking of the albumin-binding site actually
somewhat increased recycling of hIgG1 (Fig. 8f).
Discussion
Here we describe a cellular assay (HERA) that can be used for
rapid screening of hFcRn-dependent rescue from degradation of
pH 7.4 pH 7.4 pH 7.4
pH 7.4
pH 6.0 pH 6.0 pH 6.0
****
****
********
***
**
*
**
ns
ns
pH 7.4 pH 7.4
25
20
15
10
5
0
Up
ta
ke
 (n
g)
R
el
at
iv
e 
up
ta
ke
R
ec
yc
lin
g 
(ng
)
Up
ta
ke
 (n
g)
R
ec
yc
lin
g 
(ng
)
R
el
at
iv
e 
re
cy
cli
ng
R
es
id
ua
l a
m
ou
nt
 (n
g)
R
el
at
iv
e 
re
si
du
al
 a
m
ou
nt
R
es
id
ua
l a
m
ou
nt
 (n
g)
40
30
20
10
0
10
8
6
4
2
0
20
15
10
5
0
20
15
10
5
0
25
20
15
10
5
0
20
80
60
40
20
15
10
5
0
10
8
6
4
2
0
40
30
20
10
0
WT YT
E LS KF
YT
E/K
F WT YT
E LS KF
YT
E/K
F WT YT
E LS KF
YT
E/K
F
WT YT
E LS KF
YT
E/K
F WT YT
E LS KF
YT
E/K
F WT YT
E LS KF
YT
E/K
F
WT YT
E LS KF
YT
E/K
F WT YT
E LS KF
YT
E/K
F WT YT
E LS KF
YT
E/K
F
************
****
****
ns
ns
ns
ns
ns
a b c
d e f
g h i
Fig. 5 HERA screening of WT and Fc-engineered hIgG1 variants. a Uptake of WT and Fc-engineered hIgG1 variants at pH 7.4 when 400 nM of each variant
was added to the cells followed by 4 h incubation, washing and lysis of the cells. b Recycling of the Fc-engineered hIgG1 variants at pH 7.4 when 400 nM of
each variant was added to the cells and incubated for 4 h followed by extensive washing and additional 4 h incubation before sample collection. c The same
procedure as in b followed by lysis of the cells. The amounts of hIgG variants in all samples were quantified by ELISA and obtained data are shown as mean
± s.d. of four independent experiments performed in triplicates. ns> 0.05, ****p< 0.0001, by one-way ANOVA (Tukey’s multiple comparison test).
Relative d uptake, e recycling and f residual amount calculated from data (a–c), g uptake, h recycling and i residual amounts when WT and the Fc-
engineered hIgG1 variants were initially incubated at pH 6.0. The amounts of hIgG variants in all samples were quantified by ELISA, and obtained data are
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engineered hIgG and HSA variants. We utilized the endothelial
cell line HMEC1, which stably expresses hFcRn and can be grown
as adherent monolayers, and uniquely regulates rescue of both
IgG and albumin from degradation. The HMEC1-hFcRn cell line
was chosen, as endothelial cells are known to be major sites for
rescue of IgG and albumin from degradation in an FcRn-
dependent manner24,45. In addition, the cell line has been used
extensively to study intracellular FcRn-mediated trafficking of
IgG using imaging technologies17,18,38,46. The cells were grown as
confluent monolayers. FcRn ligands were added and incubated
with the cells for 4 h before the medium was removed by washing.
During this period, ligands entered the cells, and FcRn binding
and recycling or degradation was initiated. However, we lysed cell
samples at this time point and defined the amount of ligand
found intracellularly as “uptake”. In a parallel set-up, fresh
medium was instead added to collect ligand that was recycled and
released during the subsequent 4 h incubation, defined as “recy-
cling”. At this time, these cells were also lysed and the amount of
ligand found intracellularly was defined as “residual amount”. To
normalize the assay, we present the obtained values as relative to
that found for the WT ligand. We observed that the recycled and
residual amounts did not equal the amount taken up. This is
likely due to degradation, a notion that is also supported by live
imaging showing a fraction of IgG in the lysosomes at the end of
experiments.
We used the assay to characterize and compare a panel of
hIgG1 variants, with the same framework and specificity for NIP.
All contained well-characterized Fc mutations that have been
reported to improve FcRn binding and give rise to extended half-
life in mice, non-human primates and humans28,41–43,47. In
addition, we included a so-called Abdeg molecule (antibody that
enhances degradation) that is engineered to bind more strongly in
the pH range of 6.0–7.441,48. The IgG variants were added to the
medium at pH 6.0 or 7.4. While considerably more of YTE, LS
and KF were taken up and detected in the medium after recycling
compared with the WT, no major differences were detected
between these Fc-engineered variants. In contrast, cellular accu-
mulation measured as residual amount varied in that more KF
was found inside the cells. This corresponds well with the fact
that KF binds more strongly to FcRn at pH 7.4 and has a longer
retention time on the FcRn column. Comparing LS and YTE, LS
bound hFcRn almost four times more strongly than YTE at pH
5.5. However, it was not found in higher amounts inside the cells
at the start of the recycling step, nor was it more efficiently
recycled. This could be explained by stronger receptor binding at
neutral pH, but the difference in retention time between the
variants on the hFcRn-coupled column is minor.
Furthermore, we determined the half-life of the panel of anti-
NIP hIgG1 variants in WT and hFcRn transgenic mice and
measured profound differences in the two strains, which mirror
their distinct binding properties toward the mouse and human
forms of FcRn28–31. Again, this highlights the importance of
considering cross-species differences when measuring pharma-
cokinetics. Importantly, the calculated HERA scores for the
hIgG1 variants were shown to correlate with in vivo half-life in
hFcRn transgenic mice, but not WT mice. The assay is fast and
convenient and we find it extremely useful and also sensitive.
Furthermore, we found that the sensitivity could be increased by
doing the initial uptake step at pH 6.0.
FcRn is predominantly found to be expressed within endoso-
mal compartments, while only a minor fraction is displayed at or
near the cell surface at least in parenchymal cells18,19. The
influence of pH on FcRn-mediated uptake and trafficking of IgG
in different types of cells is a matter of debate49,50. Due to neg-
ligible FcRn binding of IgG at neutral pH, cellular uptake may
solely be dependent on fluid-phase pinocytosis, but data also
support active involvement of FcRn51. The Fc-engineered var-
iants with increased binding at pH 7.4 may thus engage FcRn at
the cell surface or in early endosomes more efficiently than the
WT. Our findings show that more of the WT and Fc-engineered
variants were detected inside the cells when incubation was done
at pH 6.0. This may support the notion above, but incubation at
acidic pH will also prevent release during exocytosis and as such
promote accumulation inside the cells. This is also supported by
imaging, where the WT and IHH variants were taken up in equal
amounts when given to the cells at pH 7.4. More of the WT was
taken up than IHH when the assay was performed at pH 6.0. In
line with this, when cells were treated with siRNA targeting FcRn,
we found that uptake of WT hIgG1 was not dependent on the
receptor, while active FcRn-mediated uptake was measured for
the YTE/KF mutant variant. As FcRn is expressed as a fusion with
a C-terminal EGFP, HERA may be combined with imaging stu-
dies to gain further mechanistic insights into how FcRn binds and
transports therapeutics.
We found the KF mutant to have a similar HERA score and
half-life as WT hIgG1 in hFcRn transgenic mice. It bound hFcRn
with 3.3 µM affinity at neutral pH, while LS, which was more
efficiently rescued, bound hFcRn with an affinity of 7 µM at this
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pH. This means that the affinity threshold to achieve efficient
recycling and release lies between 3–7 µM as defined by Micro-
Scale Thermophoresis. Notably, it has previously been shown that
high affinity at acidic pH combined with binding affinity up to
0.8 µM at neutral pH, as defined by surface plasmon resonance
measurements, resulted in extended half-life52.
While relative uptake and rescue of the three hIgG1 variants,
YTE, LS and KF, were similar at the two pH conditions, this was
not the case for YTE/KF, which was distinctly different regarding
uptake, recycling and residual amount remaining inside the cells.
The amount of YTE/KF recycled represented a minor fraction of
the total pool of YTE/KF that was taken up and accumulated
inside the cells, which is in accordance with live-imaging stu-
dies41,46. The distinct distribution of YTE/KF is mirrored by its
nM affinity at pH 5.5, more than 100-fold stronger than the WT,
and sub-μM affinity at pH 7.4, roughly 10-fold weaker than at pH
5.5. Our study thus demonstrates that both the amounts recycled
and remaining inside the cells should be measured to make a
useful prediction of how hFcRn-expressing cells will sort ligand
variants in vivo. Thus, the residual amount of ligands was taken
into consideration when calculating the HERA score, as well as
the amount recycled.
We also adopted HERA to study HSA variants, and again,
recycling was shown to depend on hFcRn, as only WT HSA and
not a null binding mutant was rescued. Further, a HSA variant
(K573P) engineered for improved pH-dependent FcRn binding
showed enhanced recycling and a HERA score of 2.5, which
mirrors its extended half-life in hFcRn transgenic mice and
cynomolgus monkeys35.
Although it is well-established that both IgG and albumin bind
FcRn in a similar pH-dependent manner11–14, we found a distinct
difference in dissociation as WT HSA was shown to elute earlier
from the hFcRn column (pH 6.5) than WT hIgG1 (pH 7.0). This
finding may shed new light on how the two ligands are trans-
ported in different cell types through a pH gradient. With regard
to engineering for enhanced rescue, it suggests that “the window
for improvement” is wider for HSA than for IgG. Moreover, we
showed that the ligands are transported by FcRn in the absence of
the other, and the presence of rituximab did not negatively affect
HSA rescue, but instead had a slightly enhancing effect.
Studies in mice have shown that the levels of endogenous IgG
are considerably reduced in the presence of YTE/KF41,46,48. We
therefore used the YTE/KF variant to study transport of hIgG1
and HSA in HERA. In the presence of excess amounts of YTE/
KF, where most of the IgG binding sites on hFcRn are expected to
be occupied, reduced rescue of WT anti-hexon hIgG1 was
observed, which was not observed in the presence of rituximab. In
contrast, rescue of HSA was not affected. This pin points that
HSA is still recycled and released when IgG is bound to the
receptor, which is in line with data showing that YTE/KF is not
affecting receptor trafficking, but instead hijacks the receptor
throughout the endosomal pathway41,53. When hIgG1 was given
in the presence of an engineered HSA variant that binds strongly
and less pH dependently, the antibody was recycled somewhat
more efficiently than in the presence of WT HSA. Notably, while
uptake of hIgG1 was unaffected in the presence of the engineered
albumin variant, the presence of WT HSA reduced uptake of the
antibody. Whether this reflects biology or is an artefact due to the
large amounts of WT HSA added needs to be further investigated.
In addition to the direct interaction between FcRn and its
ligands, there are several additional factors that may contribute to
define half-life, such as the expression level and availability of the
target antigen, which may enhance clearance. Thus, HERA is
expected to only correlate with half-life when the clearance
mechanism is studied at dose levels dominated by FcRn binding
and transport. However, HERA should be an attractive tool to
study how the presence of soluble antigen is affecting cellular
transport of the immune complex as well as how engineering for
pH-dependent antigen binding is affecting recycling and release
of the ligand and antigen, respectively54,55.
Further, it was recently shown that the pI of IgG may influence
cellular uptake55. In addition, the choice of framework can affect
the pI, and thus the half-life56. It is also a matter of debate
whether the Fab arms may influence FcRn binding. Support for
this has been provided using hydrogen–deuterium exchange mass
spectrometry, which indicated that there may either be a direct
interaction or possibly a conformational link between the Fab
arms and the constant Fc during complex formation with the
receptor57. A direct role of the Fab arms has been shown to
depend on the charge of the Fv part, as IgGs with differences in
charge have a great influence on pH-dependent dissociation from
an hFcRn-coupled column58 and receptor-binding kinetics59. The
effect of such structural differences on uptake and FcRn-mediated
sorting may be addressed using HERA. However, during early
stage development, it is important to eliminate antibodies with
off-target reactivity. This may be done using assays assessing
binding to panels of non-cognate proteins60–62. Interestingly, it
was recently shown that this may simply be done by screening the
antibodies towards recombinant chaperone proteins that corre-
lated with clearance in mice63. After such exclusion, HERA may
be an attractive tool for screening and ranking not only mono-
clonal IgG antibodies and Fc-engineered variants, but also other
formats such as anti-FcRn blocking reagents, Fc and albumin
fusions as well as immunoconjugates prior to in vivo studies.
Methods
Cell culture. HEK293E cells (ATCC, Manassas, VA, USA) and the J558L murine
myeloma cell line stably producing NIP-specific hIgG1-IHH were cultured in
Table 2 Serum half-life data in WT and humanized FcRn mice
IgG1 variants IgG1 specificity Route Dose (mg/kg) Half-life (days) (n= 5) ±s.d. (days) Mouse strains
WT 8.4 2.5
Tg32 hemizygous mice
YTE 12.6 1.2
LS
anti-NIP IV 5
11.2 2.2
KF 7.6 1.0
YTE/KF 3.3 0.3 Tg32 homozygous mice
WT 4.9 0.4
WT mice
YTE 3.6 0.6
LS
anti-NIP IV 5
4.6 1.2
KF <2.0
YTE/KF <2.0
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RPMI 1640 (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal calf
serum (FCS) (Sigma-Aldrich), 2 mM L-glutamine, 25 μg/ml streptomycin, and 25
U/ml penicillin (all from Bio Whittaker). The parental human microvascular
endothelial cell line (WT HMEC1) and HMEC1 stably expressing HA-hFcRn-
EGFP (HMEC1-hFcRn)38 were grown in MCDB 131 medium (Gibco) supple-
mented with 10% heat-inactivated FCS, 2 mM L-glutamine and 25 µg/ml strepto-
mycin, and 25 U/ml penicillin, 10 ng/ml mouse epidermal growth factor
(PeproTech) and 1 µg/ml hydrocortisone (Sigma-Aldrich). Medium for HMEC1-
hFcRn was also supplemented with 5 µg/ml blasticidin (InvivoGen) and 100 µg/ml
G418 (Sigma-Aldrich) to maintain stable expression of hFcRn. High five cells
(Invitrogen) were grown in Express FIVE SEF medium (Invitrogen) supplemented
with 18 mM L-glutamine and 1% antibiotic–antimyotic (Invitrogen). All cell lines
were negative for mycoplasma contamination (MycoAlertTM PLUS Mycoplasma
detection kit, Lonza).
Production of hIgGs. Vectors encoding the WT and mutated hIgG1 HC variants
with specificity for NIP and adenovirus 5 hexon have previously been repor-
ted44,64,65. The vectors were transiently transfected into HEK293E cells using
Lipofectamine 2000 as described by the manufacturer (Life Technologies). Cells
were co-transfected with plasmids encoding light chains with the corresponding
specificity64,65. Production of an anti-NIP hIgG1-IHH variant was done using a
previously described J558L murine myeloma cell line stably transfected with
pLNOH2-NIPhIgG1-IHH, which also constitutively expresses the anti-NIP mouse λ
light chain26. Growth medium was harvested and replaced every second day for
2 weeks prior to purification using a CaptureSelectTM pre-packed anti-hIgG-CH1
column (Life Technologies) as described by the manufacturer. The collected pro-
teins were up-concentrated and buffer-changed to phosphate-buffered saline (PBS)
(Sigma-Aldrich) using Amicon Ultra-15 ml 50K columns (Millipore) prior to size
exclusion chromatography using a Superdex 200 increase 10/300GL column (GE
10
0
20
0
40
0
80
0
16
00
32
00 10
0
20
0
40
0
80
0
16
00
32
00
40
30
20
10
0
WT
K573P
pH
gradient
WT
K5
73
P WT
K5
73
P
WTWT MS
A
K5
00
A
WT
K5
73
P
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
1.0
0.8
0.6
0.4
0.2
0.0
–0.2
Retention time (min)
30 35 40 45 50 55 60
8
6
4
2
0
4
3
2
1
0
2.0
1.5
1.0
0.5
0.0
R
el
at
iv
e 
re
cy
cli
ng
R
el
at
iv
e 
re
cy
cli
ng
R
ec
yc
lin
g 
(ng
)
R
es
id
ua
l a
m
ou
nt
 (n
g)
Up
ta
ke
 (n
g)
pH
 g
ra
di
en
t
R
el
at
iv
e 
flu
or
es
ce
nc
e 
A 
(28
0)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
W
T 
H
SA
 re
cy
cli
ng
 (n
g)
W
T 
H
SA
 re
cy
cli
ng
 (n
g)
pH 7.42.0
1.6
1.2
0.8
0.4
0
pH 6.0 pH 7.4 pH 7.4
pH 7.4pH 7.4pH 7.49.01.2
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.1 1 10 10
0
10
00
10
,00
0
10
0,0
00
1.2
1.4
1.0
0.8
0.6
0.4
0.2
0.0
–0.2
1.2
1.4
1.0
0.8
0.6
0.4
0.2
0.0
–0.2
Fr
ac
tio
n 
bo
un
d
Fr
ac
tio
n 
bo
un
d
R
el
at
iv
e 
re
cy
cli
ng
R
el
at
iv
e 
re
cy
cli
ng
R
el
at
iv
e 
re
cy
cli
ng
R
el
at
iv
e 
re
cy
cli
ng
pH 7.4 pH 7.4 pH 7.4 pH 7.4 WT
pH 7.4
pH 5.5 pH 5.5
pH 7.4
K573P
hFcRn (nM)
1 10
WT
WT
 + 
AD
M1
2WT
WT
 + 
DV
N2
4
10
0
10
00
10
,00
0
10
0,0
00
hFcRn (nM)
WT
WT
 + 
siR
NA
Co
ntr
ol
WT
 + 
siR
NA
hF
cR
n
WT
 + 
AD
M3
1
DII
K500A
K573P
HSA
DI
DIII
WT HSA added to cells (nM) WT HSA added to cells (nM)
6
5
4
3
2
1
0
a b c d e
f g h i j k
l m n o
Fig. 7 HERA screening of HSA variants. Recycling of WT HSA at a pH 7.4 and b pH 6.0 after 4 h incubation with titrated HSA concentrations (100–3200
nM). c An illustration of the crystal structure of HSA with the amino acid residues targeted by mutagenesis (K500A and K573P) highlighted in red spheres.
The figure was designed using the PyMOL software with the crystallographic data of HSA70. Histograms showing relative recycling of d WT HSA and
K500A, e HSA and MSA, f WT HSA by HMEC1-FcRn cells transfected with a control or hFcRn-specific siRNAs. Relative recycling of WT HSA in the
absence or presence of either g ADM31 (binds the HSA binding site on hFcRn), h DVN24 (binds the IgG binding site on hFcRn) or i ADM12 (does not bind
the ligand binding sites). MicroScale Thermophoresis measurements where j WT HSA-EGFP and k HSA-K573P-EGFP at a constant concentration (100
nM) were added to titrated amounts of hFcRn at pH 5.5 and 7.4. Binding data were derived from the specific change in thermophoretic mobility and the
ratio of normalized time-averaged (1 s) fluorescence intensities at defined time points of the MicroScale Thermophoresis traces (−1 and 4 s). The data from
three independent experiments with three replicates are shown where error bars show± s.d. l Analytical hFcRn affinity chromatography of WT and K573P.
The elution profiles are shown as relative fluorescence intensity and as a function of a pH gradient. m Uptake, n recycling and o residual amounts when
equal amounts of WT and K573P were added at pH 7.4. The amounts of HSA variants were quantified using ELISA. The obtained data are shown as mean
± s.d. of two independent experiments performed in triplicates
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03061-x
10 NATURE COMMUNICATIONS |  (2018) 9:621 |DOI: 10.1038/s41467-018-03061-x |www.nature.com/naturecommunications
Healthcare) and an ÄKTA FPLC instrument (GE Healthcare). The monomeric
fractions were up-concentrated by Amicon Ultra-0.5 ml 100K columns (Millipore).
Production of HSA variants. The cDNA fragment of full-length HSA was cloned
into a pcDNA3.1 (Invitrogen), and cDNA fragments encoding DIII variants
(K573P, K500A and E505Q/T527M/V547A/K573P; EQTMVAKP) were ordered
(GenScrip, NJ, USA), and sub-cloned into pcDNA3.1-HSA using the restriction
sites of BamHI and XhoI. In addition, cDNA sequences encoding WT HSA and
K573P with a C-terminal glycine-serine linker ((GGS)4GG) were ordered (Gen-
Script) and sub-cloned in a frame of a gene encoding EGFP in pEGFP-N1
(Clontech Laboratories) using the restriction sites of XhoI and HindIII. All HSA
variants were produced in adherent HEK293E cells by transient transfection using
Lipofectamine 2000 (Life Technologies). Growth medium was harvested and
replaced for up to 2 weeks prior to purification using CaptureSelect HSA affinity
matrix (Life technologies) packed in a 5 ml column (Atoll). Elution from the
column was done using 20 mM Tris, 2 M MgCl2 pH 7.4. Collected proteins were
up-concentrated and buffer-changed to PBS (Sigma-Aldrich) using Amicon Ultra-
15 ml 30K columns (Millipore) prior to size exclusion chromatography using a
Superdex 200 increase 10/300GL column (GE Healthcare) and an ÄKTA FPLC
instrument (GE Healthcare). Monomeric fractions were up-concentrated by
Amicon Ultra-0.5 ml 30K columns (Millipore).
Production of recombinant hFcRn. Truncated monomeric His-tagged hFcRn was
produced using a Baculovirus expression system39,66. The viral stock was a kind gift
from Dr. Sally Ward (University of Texas, Southwestern Medical Center, Dallas,
USA). Briefly, high five cells were cultured at 1 × 106 cells/ml at 27 °C with gentle
agitation (160 rpm), before cells (500 ml, 1 × 106 cells/ml) were infected with 1 ml
virus stock (Autographica californica nuclear polyhedrosis virus harbouring the
pAxUW51 plasmid encoding cDNA of the three extracellular domains of hFcRn
HC fused with a His6-tag and human β2-microglobulin). After 72 h at 24 °C post
infection, the supernatant was harvested, and the receptor was purified using a
HisTrap HP column supplied with Ni2+ ions (GE healthcare). After column
equilibration with PBS containing sodium azide (0.05%), the supernatant was
adjusted to pH 7.2 and applied on the column with a flow rate 5 ml/min, then the
column was washed with 200 ml PBS followed by 50 ml PBS containing 25 mM
imidazole pH 7.3, and bound hFcRn was eluted with 50 ml PBS containing 250 mM
imidazole. Amicon Ultra 10K columns (Millipore) were used for up-concentration
and buffer-change to PBS (Sigma-Aldrich) prior to size exclusion chromatography
using a HiLoad 26/600 Superdex 200 prep grade column (GE Healthcare) coupled
to an ÄKTA FPLC instrument (GE Healthcare). Monomeric receptor was up-
concentrated by Amicon Ultra-0.5 ml 10K columns (Millipore) and stored at 4 °C.
HERA. 7.5 × 105 HMEC1 cells stably expressing HA-hFcRn-EGFP were seeded into
24-well plates per well (Costar) and cultured for 2 days in growth medium. The
cells were washed twice and starved for 1 h in Hank’s balanced salt solution (HBSS)
(Life Technologies). Then, 400 nM of either hIgG1, mIgG1 or 1600 nM of WT HSA
and MSA (Calbiochem) were diluted in 250 µl HBSS (pH 7.4) and added to the
cells followed by 4 h incubation. The medium was removed and the cells were
washed four times with ice cold HBSS (pH 7.4), before fresh warm HBSS (pH 7.4)
or growth medium without FCS and supplemented with MEM non-essential amino
acids (ThermoFisher) was added. Samples were collected at 4 h or ON. For com-
petition studies, 800 or 3200 nM of DVN24, ADM12 and ADM3139,40 were diluted
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into 200 µl and added to the cells followed by 30 min incubation. The medium was
removed and 400 nM anti-NIP hIgG1 or 1600 nM HSA together with DVN24,
ADM12 and ADM31 were added. Five hundred nM anti-hexon hIgG1 and WT
HSA were mixed with 2 µM anti-NIP hIgG1-YTE/KF or 8 µM rituximab (Roche)
in 250 µl HBSS (pH 7.4) and added to the cells. The following steps were performed
as described above.
The amounts of anti-NIP or anti-hexon hIgG1 or HSA variants were quantified
using ELISA as described below. HERA was also performed where the initial step
was done at pH 6.0 using HBSS containing 7 mM MES buffer (Sigma-Aldrich),
200 nM of hIgG1, and the following steps as described above. Total protein lysates
were obtained using the CelLytic M cell lysis Reagent (Sigma-Aldrich) or RIPA
lysis buffer (ThermoFisher) supplied with a protease inhibitor cocktail (Sigma-
Aldrich) or complete protease inhibitor tablets (Roche). The mixture was incubated
with the cells on ice and a shaker for 10 min followed by centrifugation for 15 min
at 10,000 × g to remove cellular debris. Quantification of the amounts of hIgG1 or
HSA variants present in the lysates was done by ELISA.
The derived values for recycling and residual amount for each of the IgG1
variants were used to calculate the HERA score. The following formula was used:
(RX/RWT)/(RAX/RAWT). The parameter R (in ng) is recycling at a given time while
RA (in ng) is the residual amount. X is the protein of interest while WT is the
parental variant used to standardize results.
Quantification of IgG. Ninety-six well plates (Costar) were coated with 1 µg/ml of
bovine serum albumin (BSA) conjugated to NIP (BSA-NIP) (Biosearch Technol-
ogies, Inc.), recombinant AdV5 hexon (AbD Serotec) or polyclonal anti-human or
mouse Fc-specific antibody from goat (locally produced) diluted (0.2 µg/ml) in
PBS. After incubation ON at 4 °C, plates were blocked with PBS containing 4%
skimmed milk (S) (Sigma-Aldrich) for 1 h at room temperature (RT) and washed
four times with PBS containing 0.05% Tween 20 (T) (Sigma-Aldrich). Serial
dilutions of IgGs (250.0–0.1 ng/ml) were added in parallel with samples collected
from HERA and incubated for 2 h at RT. The plates were washed four times as
above, before alkaline phosphatase-conjugated polyclonal anti-mIgG or hIgG Fc-
Ab from goat (#A2429, #A9544, Sigma-Aldrich), diluted (1:4000) in 4% PBS/S/T,
was added for 1.5 h at RT. The plates were washed as above before 100 µl of the p-
nitropenylphospate substrate (Sigma-Aldrich) diluted to 10 µg/ml in diethanola-
mine buffer was added. The absorbance was measured at 405 nm using a Sunrise
spectrophotometer (TECAN).
Quantification of albumin. Ninety-six-well ELISA plates (Costar) were coated
with 1.0 µg/ml of polyclonal goat anti-HSA (#A1151, Sigma-Aldrich) or polyclonal
anti-MSA (#ab19194, Abcam) antibodies, 1.0 µg/ml diluted in PBS, and incubated
ON at 4 °C. Plates were blocked with PBS/S ON at 4 °C and washed four times with
PBS/T before serial dilutions of MSA or HSA (250.0–0.1 ng/ml) in PBS/S/T were
applied in parallel with samples from HERA followed by 2 h incubation at RT.
Bound MSA and HSA were detected using horseradish peroxidase-conjugated
polyclonal anti-MSA antibody from goat (#ab19195; Abcam, 1:4000) or alkaline
phosphatase-conjugated polyclonal anti-HSA antibody from goat (#A80229AP;
Bethyl Laboratories, Inc., 1:5000). ELISAs were developed by adding 100 µl of 3,3
´,5,5´-tetramethylbenzinide solution (Calbiochem) and the reaction was stopped by
adding 100 µl of 1 M HCl for MSA, while for HSA 100 µl of the p-nitropenyl-
phospate substrate (Sigma-Aldrich) diluted to 10 µg/ml in diethanolamine buffer
was added. The absorbance was measured at 450 or 405 nm using a Sunrise
spectrophotometer (TECAN).
Quantification of hFcRn. Membrane-bound proteins were extracted from WT
HMEC1 and HMEC1-hFcRn cell lines using a Native Membrane Extraction kit as
described by the manufacturer (Calbiochem). The final fractions were stored at
−80 °C until analysed in ELISA. Ninety-six-well plates (Costar) were coated with 8
µg/ml of hIgG1-YTE/KF and incubated overnight at 4 °C before plates were
blocked with PBS/S for 1 h at RT and then washed four times with PBS/T at pH 5.5
(100 mM phosphate buffer, 0.15M NaCl, 0.05% Tween 20). Serial dilutions of
hFcRn (500.0–0.2 ng/ml) in PBS/S/T pH 5.5 were added in parallel with 2 µg of
extracted membrane proteins followed by incubation for 2 h at RT. The plates were
washed four times as above, before 1 µg/ml of biotinylated ADM31 was added and
incubated for 1.5 h at RT followed by washing and detection using alkaline
phosphatase-conjugated streptavidin (GE healthcare) diluted (1:3000) in PBS/T pH
5.5. The plates were washed as above before 100 µl p-nitropenylphosphate (10 µg/
ml) diluted in diethanolamine buffer was added. The absorbance was measured at
405 nm using a Sunrise spectrophotometer (TECAN).
SDS-PAGE and western blotting. Extracted membrane protein fractions from
HMEC1-hFcRn cells treated with a mixture of control siRNA or siRNA targeting
the hFcRn HC were separated on a non-reducing 12% Bis-Tris plus gel (Invitro-
gen) and transferred onto a polyvinylidene fluoride membrane (Millipore) in Tris/
glycine buffer (25 mM Tris, 192 mM glycine, and 20% methanol, pH 8.3) at 25 V
for 30 min using a semi-dry blotting apparatus (Bio-Rad). The membrane was
blocked with PBS/S/T before added horseradish peroxidase-conjugated anti-HA-
tag polyclonal Ab produced in goat (#ab1265, Abcam, 1:5000) to detect HA-tagged
hFcRn. The membrane was washed four times with PBS/T and developed with a
SuperSignal West Femto substrate (Pierce) and image acquired by the G:BOX
instrument (Syngene).
FcRn-IgG binding ELISA. Ninety-six-well plates (Costar) were coated with 2 μg/ml
of BSA-NIP (Biosearch Technologies, Inc.) diluted in PBS and incubated ON at 4 °
C. Plates were blocked with PBS/S for 1 h at RT and then washed four times with
PBS/T. Serial dilutions of WT IgG1 and Fc-engineered variants (10,000–1.5 ng/ml)
in PBS/S/T were added and incubated for 1 h at RT. The plates were washed four
times as above, before site-specific biotinylated mFcRn and hFcRn (2.5 μg/ml)
(Immunitrack) diluted in PBS/S/T pH 5.5 (100 mM phosphate buffer, 0.15 M NaCl,
4% skimmed milk, 0.05% Tween 20) or PBS/S/T pH 7.4 was added followed by
incubation for 1 h at RT. After washing four times with either pH 5.5 or pH 7.4
PBS/T, alkaline phosphatase-conjugated streptavidin (GE Healthcare) diluted
(1:3000) in pH 5.5 or pH 7.4 PBS/S/T was added for 1 h at RT. The plates were
washed as above before 100 μl of the p-nitropenylphospate substrate (Sigma-
Aldrich) diluted (10 μg/ml) in diethanolamine buffer was added. The absorbance
was measured at 405 nm using a Sunrise spectrophotometer (TECAN).
FcRn-HSA binding ELISA. Ninety-six-well ELISA plates (Costar) were coated with
8 μg/ml of hIgG1-YTE/KF diluted in PBS, and incubated ON at 4 °C. Plates were
blocked with PBS/S for 1 h at RT, and then washed four times with PBS/T. His-
tagged hFcRn (10 μg/ml) in pH 5.5 or pH 7.4 PBS/S/T was added and incubated for
1 h at RT. The plates were washed four times with either pH 5.5 or pH 7.4 PBS/T,
before serial dilutions (15,000–7.3 ng/ml) of WT HSA or HSA-EQTMVAKP in pH
5.5 or pH 7.4 PBS/S/T were added, and incubated for 1 h at RT. The plates were
washed four times as above, before alkaline phosphatase-conjugated polyclonal
anti-HSA antibody from goat (#A80229AP; Bethyl Laboratories, Inc., 1:5000),
diluted (1:3000) in pH 5.5 or pH 7.4 PBS/S/T was added for 1 h at RT. The plates
were washed four times and developed as above.
MicroScale Thermophoresis assay. A Monolith NT.115 instrument (Nano
Temper Technologies GmbH, Munich, Germany)67 was used where anti-NIP
hIgG1 variants labelled with NT-647-HNS fluorescent dye (Nano Temper Tech-
nologies) or C-terminally EGFP-fused HSA variants were used. Titrated amounts
of hFcRn (60,000–0.3 nM) were incubated with 20 nM of each of the labelled hIgG1
variants or 100 nM HSA-EGFP at RT for 10 min in PBS pH 7.4 or 100 mM
phosphate buffer (6 mM Na2HPO4×2H2O, 94 mM NaH2PO4×H2O, 150 mM NaCl)
pH 5.5, both buffers supplemented with 0.01% T. Samples were loaded onto
premium-coated capillaries (Nano Temper Technologies). Measurements were
performed at 25 °C using 40% LED and 40% MicroScale Thermophoresis power for
hIgG1 variants, and 80% LED and 60% power for HSA-EGFP variants. All
experiments were repeated three times for each measurement, and data analyses
were done using Nano Temper analysis software.
Analytical hFcRn affinity chromatography. Analytical hFcRn affinity chroma-
tography was performed using an ÄKTA Avant 25 instrument (GE Healthcare),
essentially as previously described58,68. Briefly, 50 µl WT hIgG1 and Fc-engineered
variants (1 mg/ml) were injected and eluted by a linear pH gradient from pH 6.0 to
8.8 within 110 min using 20 mM MES sodium salt, 140 mM NaCl pH 5.5 and 20
mM Tris/HCl, 140 NaCl, pH 8.8 as eluents. To determine the elution pH at
particular retention times, the pH was monitored by a pH detector (GE Health-
care). HSA variants were analysed using 2 mg/ml followed by a pH elution gradient
from pH 5.5 to 8.8 within 110 min using the same buffers as above.
siRNA knockdown of FcRn expression. HMEC1-hFcRn cells were transfected
with a mixture of three control siRNAs or hFcRn HC-specific siRNAs (sc-37007,
sc-45632; Santa Cruz Biotechnology Inc). The sequences of hFcRn HC-specific
siRNAs are shown in Supplementary Table 2. For each transfection, a siRNA
mixture was diluted in siRNA transfection medium and transfection reagent,
essentially as described by the manufacturer (Santa Cruz Biotechnology Inc). Cells
were incubated for 6 h at 37 °C in a CO2 incubator followed by adding MCDB 131
medium with 20% FCS and 200 U/ml PS. Cells were then incubated for additional
24 h before medium was replaced with MCDB 131 medium.
Confocal laser scanning microscopy. HMEC1-hFcRn-EGFP cells were seeded in
eight-well NuncTM Lab-TekTM chambered Coverglass imaging dishes (Thermo-
Fisher Scientific), and grown to 50–70% confluency. WT and IHH hIgG1 variants
were conjugated with Alexa-647 following the manufacturer’s procedure (Life
Technologies). Cells were washed three times with HBSS pH 6.0 and Alexa-647
conjugated antibodies, diluted in HBSS pH 6.0 to the final concentration of 400
nM, were added to the cells and incubated for 4 h before pictures were taken. The
cells were then washed three times with HBSS pH 7.4, and incubated in HBSS pH
7.4 for 4 h before pictures were taken. Lysotracker DND-99 (Life Technologies) was
added to the cells 30 min before pictures were taken. Confocal images were
acquired on an Olympus FluoView 1000 inverted microscope equipped with a
PlanApo 60/1.42 oil objective (Olympus). Constant temperature was set to 37 °C
and CO2 to 5% by an incubator enclosing the microscope stage. Image acquisition
was done by sequential line scanning to eliminate bleed-through. Images were
processed and prepared with ImageJ (NIH), Adobe Photoshop and Illustrator
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(Adobe system Inc). Co-localization was quantified using Imaris spot co-
localization software (Bitplane) where the endosome size was set to 1 µm. Data
from two independent experiments with 15–20 cells analysed were used for co-
localization analysis.
In vivo studies. Hemizygous Tg32 mice (B6.Cg-Fcgrttm1Dcr Tg(FCGRT)32Dcr/
DcrJ; The Jackson Laboratory) that are transgenic for the hFcRn gene and WT
mice (BALB/c; Taconic) were used to determine the half-life of the hIgG1 anti-
bodies, except for YTE/KF that was evaluated in homozygous Tg32 mice. Male
mice, age 7–9 weeks, weighing between 17 and 27 g (5 mice per group), received 5
mg/kg of hIgG1 variants diluted in PBS by intravenous injections. Blood samples
(25 µl) were drawn from the retro-orbital sinus of the Tg32 mice at days 1, 3, 5, 7,
10, 12, 16, 19, 23, 30 and 37 after injection. WT mice had blood drawn from the
saphenous vein on days 0, 1, 2, 4, 6, 8, 10 and 12 after injection. The blood samples
were immediately mixed with 1 µl 1% K3-EDTA to prevent coagulation and then
centrifuged at 17,000 × g for 5 min at 4 °C. Plasma was isolated and diluted 1:10 in
50% glycerol/PBS solution and then stored at −20 °C until analysis by ELISA as
described above. Plasma samples were diluted 1:400 in PBS/S/T and 100 μl was
added per well in the ELISA plate. The Tg32 mice studies were carried out at The
Jackson Laboratory (JAX Services, Bar Harbor, ME), while the WT mouse study
was done at the Department of Immunology, Oslo University Hospital, Rik-
shospitalet. The experiments and procedures used were all approved by the Animal
Care and Use Committee at The Jackson Laboratory (Tg32 study) and the Nor-
wegian Animal Research Authority (BALB/c study), and were performed in
accordance with the approved guidelines and regulations.
Half-life calculation. The plasma concentration of the hIgG1 antibodies was
presented as percentage remaining in the circulation at different time points after
injection compared to the concentration on day 1 (100%). Nonlinear regression
analysis was performed to fit a straight line through the data using Prism 7. The β-
phase half-life was calculated using the formula: t1/2 = log 0.5/(log Ae/A0) × t, where
t1/2 is the half-life of the hIgG1 evaluated, Ae is the amount of hIgG1 remaining, A0
is the amount of hIgG1 on day 1 and t is the elapsed time.
Statistical analysis. Figures were generated and statistical analyses (ANOVA with
Tukey’s multiple comparisons test or Dunnett’s multiple comparison test, with a
95% confidence interval and p < 0.05 was considered a statistically significant
difference) were performed using GraphPad Prism 7 for Windows (Version 7.02;
GraphPad Software Inc.) and Microsoft Excel 2010 (Microsoft).
Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request.
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